Welcome to our dedicated page for Coya Therapeutics news (Ticker: COYA), a resource for investors and traders seeking the latest updates and insights on Coya Therapeutics stock.
Coya Therapeutics, Inc. (NASDAQ: COYA) is a clinical-stage biotechnology company advancing novel therapies that modulate regulatory T cells (Tregs) to treat neurodegenerative, autoimmune, and metabolic disorders. This page serves as the definitive source for official updates and analysis on COYA's progress in developing innovative immunology solutions.
Investors and researchers will find timely updates on clinical trial milestones, regulatory developments, and strategic collaborations. Our curated news collection includes verified information on therapy pipeline advancements, intellectual property updates, and financial disclosures essential for evaluating this innovative biotech company.
Key content focuses on COYA's multi-modality Treg platform developments, partnership announcements with research institutions, and progress toward addressing high-need conditions like ALS and Alzheimer's disease. All materials maintain journalistic rigor while avoiding speculative commentary.
Bookmark this page for structured access to COYA's latest scientific advancements and corporate developments. Check regularly for updates on this pioneering company's efforts to translate Treg research into transformative therapies.
Coya Therapeutics (NASDAQ:COYA) reported promising preclinical results for COYA 303, its investigational combination therapy of LD-IL-2 and GLP-1RA, in a mouse model of systemic and neuroinflammation. The study demonstrated significant anti-inflammatory effects both systemically and in the central nervous system.
The first cohort results showed that COYA 303 effectively reduced pro-inflammatory myeloid cells, increased anti-inflammatory immune cells, and attenuated neuroinflammation in the brain. The therapy showed particular promise in enhancing regulatory T cell (Treg) function and survival in inflammatory environments, supporting its potential application in treating Alzheimer's Disease and other neurodegenerative conditions.
The company is currently conducting additional cohort studies to evaluate modified treatment protocols, with plans to present complete findings in a peer-reviewed forum.
Coya Therapeutics (NASDAQ: COYA) announced that its Phase 2 clinical trial for COYA 302 in ALS patients has been accepted as a NEALS-Affiliated Trial by the NEALS Consortium, the world's largest ALS research network. The trial, following FDA's recent IND acceptance, is scheduled to begin in Q4 2025.
The study will be presented during the NEALS Educational Webinar on September 29, 2025, by Dr. James Berry from Mass General Hospital. As a NEALS-affiliated study, COYA 302's trial will receive broad support across NEALS' institutional and community networks, enhancing operational execution and clinical impact.
Coya Therapeutics (NASDAQ: COYA), a clinical-stage biotech company specializing in regulatory T cell (Treg) function enhancement for neurodegenerative disorders, has announced its participation in two major investor conferences in September 2025.
CEO Arun Swaminathan will present at the H.C. Wainwright Global Investment Conference on September 10 at 10 am ET at the Lotte New York Palace Hotel. The company will also attend the Lake Street Capital Markets Best Ideas Growth Conference on September 11 at The Yale Club of New York City. Management will be available for one-on-one meetings at both events.
A webcast of the presentation will be available on the company's website for 90 days.Coya Therapeutics (NASDAQ:COYA) has received FDA acceptance of its Investigational New Drug (IND) application for COYA 302, a proprietary immunomodulatory biologic combination therapy for treating Amyotrophic Lateral Sclerosis (ALS). The acceptance enables the company to proceed with a Phase 2 multicenter, double-blind, placebo-controlled clinical study to evaluate the treatment's efficacy and safety.
The milestone triggers a $4.2 million payment to Coya from its partner Dr. Reddy's Laboratories (DRL). The development represents a significant step in Coya's partnership with DRL to advance potential treatments for ALS patients.
Coya Therapeutics (NASDAQ: COYA), a clinical-stage biotech company focused on regulatory T cell enhancement for neurodegenerative disorders, reported Q2 2025 financial results and corporate updates. The company ended Q2 with $29.8 million in cash and posted a net loss of $6.1 million, wider than the $2.9 million loss in Q2 2024.
Key developments include the FDA submission for COYA 302 Phase 2 trial in ALS patients, with a decision expected by August 29, 2025. Upon IND acceptance and first patient dosing, Coya will receive $8.4 million in milestone payments from Dr. Reddy's Laboratories. The company also secured a U.S. patent for a stable ready-to-use liquid IL-2 formulation and plans to submit an IND for Frontotemporal Dementia by year-end.
Coya Therapeutics (NASDAQ: COYA) has announced the publication of a significant research study examining the relationship between inflammation, oxidative stress, and Parkinson's Disease (PD) progression. The study, partially funded by Coya and published in Frontiers of Immunology, reveals important findings about immune dysfunction in PD pathogenesis.
The research demonstrates that peripheral blood monocytes from PD patients show distinct inflammatory patterns compared to healthy controls, with key findings including: upregulation of pro-inflammatory cytokines (IL-6 and IL-1b), increased expression of chemokine receptor CCR2, and varying levels of oxidative stress markers throughout disease progression.
The company is developing COYA 302, a dual immunomodulatory treatment designed to enhance regulatory T cell (Treg) function and suppress inflammation produced by activated monocytes and macrophages. This approach aligns with the study's findings regarding the role of peripheral inflammation in PD pathophysiology.
Coya Therapeutics (NASDAQ: COYA), a clinical-stage biotech company focused on developing biologics for regulatory T cell function enhancement, has announced its participation in the upcoming BTIG Virtual Biotechnology Conference scheduled for July 29-30, 2025.
Interested parties can schedule one-on-one meetings with Coya's management team through their BTIG representatives.
Coya Therapeutics (NASDAQ: COYA), a clinical-stage biotech company focused on developing biologics for regulatory T cell function enhancement, announces its participation in the H.C. Wainwright 3rd Annual BioConnect Conference on May 20, 2025. CEO Arun Swaminathan will engage in a fireside chat at 12:30pm ET at the Nasdaq World Headquarters in New York City.
The presentation will be available via webcast, with management offering one-on-one meeting opportunities. The webcast will be accessible through Coya's website and remain available for 90 days after the event.
FAQ
What is the current stock price of Coya Therapeutics (COYA)?
What is the market cap of Coya Therapeutics (COYA)?
